This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The life sciences industry is flexing towards innovation in new areas, faster than ever before, and increasing patient care in astonishing ways. Decentralised oncology trials, for example, have shown actual predictive outcome value. We can now measure patient activity, steps, and movement continuously and in real time, which serves as a new potential indicator of treatment effectiveness. 1 And, digital therapeutics have emerged as an effective treatment for chronic diseases, including mental ill
The OK caps a long development journey for the treatment, which was previously turned back by the agency. Ferring doesn’t expect it to be available until the second half of next year, however.
Moderna and the UK government have entered a ten-year strategic collaboration to build a messenger ribonucleic acid (mRNA) research, development and manufacturing facility in the country. The latest development comes after the parties announced an agreement in principle in June this year. This Moderna Innovation and Technology Centre (MITC) is expected to offer access to a locally produced future mRNA vaccine portfolio against respiratory viruses, subject to regulatory evaluation and licensure.
Athletes scaled new heights during the 2020 Tokyo Olympics with the addition of seven new sports, including karate and climbing. But while overall injuries remained comparable to previous games, some of the new sports contributed a disproportionately large portion of them. [link] To safeguard athletes’ wellbeing the International Olympic Committee (IOC) audits injuries and illnesses […].
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Lynparza’s authorization in first-line prostate cancer comes days after U.S. regulators delayed a decision on the same indication, a potential sign of the FDA’s concerns around PARP blockers.
Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The companies entered the initial agreement in September last year. This alliance is utilising the Axiomer ribonucleic acid (RNA) editing platform of ProQR to address ailments affecting the liver and nervous system.
Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The companies entered the initial agreement in September last year. This alliance is utilising the Axiomer ribonucleic acid (RNA) editing platform of ProQR to address ailments affecting the liver and nervous system.
Restricting our food intake can result in a range of health benefits, including reducing the risk of obesity. But when the dieting stops, the weight often piles back on, and a new study in mice may have identified why. [link] Scientists from the Shanghai Institute of Nutrition and the Chinese Academy of Sciences think they […].
The proposed bill would strengthen rules around confirmatory testing, help speed product withdrawals and set up a panel of agency officials to better coordinate policy.
Fentanyl is a powerful opioid (a narcotic analgesic that is at least partly synthetic) that is being trafficked in increasing quantities from Mexico to the US by cartels. The Drug Enforcement Administration (DEA) recently announced that it had seized 10,000 pounds of illicit fentanyl in 2022 and pointed out that this volume represented enough fentanyl to kill every American.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Going outdoors more during the day might lead to slipping into sleep more easily during the night, according to a new study that found a relationship between the seasons and shifts in sleeping patterns. While the study found the number of hours of slumber banked across summer, fall, winter, and spring were similar, in the […].
The pharma dosed the first patient in a Phase 2 study testing a treatment it hopes could compete with closely-watched weight-loss drugs from Lilly, Novo Nordisk and Amgen.
Sanofi has extended the partnership with Innate Pharma for natural killer (NK) cell therapeutics in oncology. With the latest development, Sanofi will licence a NK cell engager programme that acts on B7H3 from the antibody-based NK cell engager therapeutics (ANKET) platform of Innate. Under the latest licence deal, Sanofi will make an upfront payment of $26.4m (€25m) to Innate.
Scientists have found an extremely subtle twist in the genetics of aging cells, one that seems to make them increasingly less functional as time goes on. Researchers from Northwestern University have revealed animals like mice, rats, killifish, and even humans show a gradual imbalance of long and short genes in virtually every cell in their […].
Lots of people struggle to get enough sleep — and the responsibility for fixing the problem tends to fall on the individual. Experts offer advice like reducing screen time, exercising more, or just going to bed earlier in the evening. But many restless nights can’t be solved with blackout curtains, ear plugs, or other typical suggestions.
Biotechnology firm LianBio has announced that Pfizer opted in to secure the right to develop and commercialise the respiratory syncytial virus (RSV) therapeutic candidate, sisunatovir, in Mainland China, Hong Kong, Macau, and Singapore. The deal is pursuant to the existing strategic collaboration of the companies for expanding patient access to new therapeutics in Greater China.
Indian drug regulators have sought pharmacovigilance (PV) for neuropathic pain drugs gabapentin and pregabalin due to cardiovascular related adverse event citing a study by American medical journal Cardiovascular Diabetology. PV is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine or vaccine related problem, according […].
A collaboration between academic centres in the UK has won government funding for a digital approach to dysfunctional breathing or dyspnoea, a symptom that affects around 10% of the population. The Engineering and Physical Sciences Research Council (EPSRC) has set aside £400,000 (almost $490,000) for the project, which will help fund work at the Universities of Plymouth, Salford and Stirling, and the Glasgow School of Art.
Removal of the partial study suspension, which the agency imposed last December after a case of persistent anemia, helps clear the way for Bluebird to submit an approval application early next year.
Japan has granted approval for Bristol-Myers Squibb ’s (BMS) Breyanzi (lisocabtagene maraleucel; liso-cel) as second-line therapy to treat relapsed or refractory (r/r) large B-cell lymphoma (LBCL) patients. The treatment is indicated for usage in such patients irrespective of autologous hematopoietic stem-cell transplantation status. This approval is based on clinical trial findings in subjects with r/r aggressive B-cell non-Hodgkin lymphoma following first-line therapy.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
The National Accreditation Board for Hospitals & Healthcare Providers (NABH) has announced four days dental healthcare service providers’ assessors’ training programme as per second edition of Dental Healthcare Service Providers Accreditation Standards between January 17 and January 20, 2023 in New Delhi. Last Date to receive applications is December 24, 2022.
Probiotic bacteria usually found in fermented foods, such as yogurt, sourdough bread, and miso soup, might help dispel the embarrassment of persistent bad breath (halitosis), finds a pooled data analysis of the available evidence, published in the open access journal BMJ Open.
The company said its experimental drug helped patients with the fatty liver disease while also improving fibrosis. One analyst called the readout a “major win” for Madrigal and the NASH field.
Catalyst Pharmaceuticals has signed a definitive agreement with Eisai to acquire the US commercial rights for the latter’s anti-epileptic drug (AED), Fycompa (perampanel) CIII. Under the deal terms, Catalyst will also have an exclusive period to assess, review, and negotiate to buy a rare epilepsy asset in Eisai’s pipeline. Eisai will retain its rights to Fycompa in countries outside the US.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
The Indian Pharmacopoeia Commission (IPC) has flagged drug safety alert to the Drugs Controller General of India (DCGI) revealing that Minoxidil is associated with adverse event known as folliculitis. IPC is the National Coordination Centre (NCC) for Pharmacovigilance Programme of India (PvPI).Minoxidil topical solution has been approved in India for the treatment of hair loss […].
Using machine learning and clinical data from electronic health records, researchers at the Icahn School of Medicine at Mount Sinai in New York constructed an in silico, or computer-derived, marker for coronary artery disease (CAD) to better measure clinically important characterizations of the disease.
Glofitimab, part of a long-standing collaboration between the two companies that’s resulted in Rituxan and Ocrevus, will be the responsibility of Roche, which will pay out royalties.
The US Food and Drug Administration (FDA) has granted approval for AbbVie ’s Vraylar (cariprazine) as an adjunctive treatment to antidepressants to treat adult patients with major depressive disorder (MDD). The latest approval is based on clinical findings showing efficacy and well-established tolerability of this therapy. The new indication offers a new option for adult patients with partial response to antidepressant treatment.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
97 
Let's personalize your content